Eli Lilly selected Huntsville, Alabama for a $6 billion active pharmaceutical ingredient manufacturing facility focused on peptides and small molecules, including production capacity for GLP‑1 candidate orforglipron. The plant is the third of four large U.S. manufacturing sites Lilly plans; construction is slated to start in 2026 with completion targeted in the early 2030s. The investment underlines continued onshoring of critical API capacity for high‑demand therapeutics and reflects strategic vertical integration to secure supply for next‑generation obesity and metabolic medicines. The project also ties into workforce development and regional biotech infrastructure planning. Source: Lilly corporate announcement and state economic development statements.